Tunable Human ECM Platform Technology

One breakthrough platform enabling multiple biomedical applications - from neural interfaces that truly integrate with human tissue to cell therapies that work in challenging deployment scenarios.

Platform Overview

Founded by biomaterials veterans with 74+ combined patents, we've developed the first tunable hybrid biomaterial system using human collagen that enables what synthetic materials cannot achieve

Our proprietary platform creates tunable hybrid biomaterials using human collagen from cultured fibroblasts. This breakthrough technology - protected by US Provisional patents - represents one of the first applications using human collagen to create materials with precisely adjustable properties.

The platform combines human atelopeptide collagen with advanced polymer systems to create hybrid biomaterials with tunable rheological properties, enhanced thermal stability, and superior biocompatibility. This enables functionalization with other human ECM proteins from the same core process, plus integration of biological actives including antibodies, growth factors, and cytokines.

Manufacturing Infrastructure

Scalable Human Collagen Manufacturing from Cells

GMP-Ready Production Through CDMO Partners

Our platform technology is designed for seamless integration with established contract development and manufacturing organization (CDMO) partners who provide GMP-grade bioreactor systems for scalable human collagen production.

CDMO Manufacturing Capabilities:

Off-the-shelf bioreactor systems optimized for human cell culture
Scalable production from research to commercial volumes
GMP-compliant facilities with validated processes
Integrated quality control and release testing
Regulatory documentation and audit trail support

This partnership approach enables rapid scale-up without capital-intensive infrastructure investment while ensuring regulatory compliance and government contracting readiness from development through commercial production.

Platform Advantages:

Every application - from neural interfaces to advanced Biomedcial applications - builds on the same validated technology foundation, accelerating development while reducing regulatory and financial risk. The TBI repair technology, BMI interfaces, and Ambient Biostasis products all share this core platform, enabling rapid development of new products with reduced costs.

Shared Manufacturing Infrastructure:

Multiple high-value applications leverage the same GMP production capabilities through our CDMO partner network, reducing development time and regulatory risk for new products while maintaining consistent quality standards.

We can produce high-purity, biocompatible human collagen, a critical component in all our medical devices, by utilizing engineered fibroblast cells to generate extracellular matrix (ECM) proteins that enhance the functionality and compatibility of our products. This advanced bio-hybrid technology allows us to create versatile medical device solutions that address a wide range of biomedical needs.

ANCHOR Qualification Infrastructure

ADAPTIVE NATIVE COLLAGEN HYDROGEL FOR ORGAN READINESS

Beyond our core platform technology, we're developing shared qualification infrastructure that enables multiple bioprinting teams to transition from animal-derived materials to translation-ready human biomaterials. This qualification framework addresses the bottleneck preventing widespread adoption of human collagen inputs in advanced biomedical applications.

TBI & Neocortical Repair

Structured Cortical Reconstruction Using Human ECM Technology

Focal neocortical injury from stroke, trauma, or neurodegeneration produces irreversible functional loss because adult cortex lacks the developmental framework required for organized structural reconstruction.

Our breakthrough approach uses structurally engineered neocortical precursor tissue defined by multi-omics mapping and controlled extracellular matrix architecture rather than cellular differentiation alone.

Technical Innovations:

• iPSC-derived neural and mesenchymal progenitors

• Embedded in tunable human collagen-CMC backbone

• Replicates developmental ECM composition

• Engineered for laminar cytoarchitecture restoration

Brain-Machine Interface (BMI)

Our cutting-edge Brain-Machine Interface (BMI) technology represents the next frontier in medical innovation. Utilizing our human collagen platform, this device enhances neural interfaces, enabling groundbreaking applications in neurology and prosthetics.

Our neural interfaces leverage the platform's unique thermal stability and biocompatibility. Unlike synthetic polyimides, our tunable human ECM materials truly integrate with neural tissue, enabling long-term stability impossible with conventional approaches.

Key Advantages:

• Superior tissue integration

• Reduced immune response

• Extended operational lifespan

• Defense-grade reliability

Manufacturing an All Natural Neural Interface for Ultra High Density Arrays

Our Goal is a biological BMI with Tissue-like Channel Density

Ambient Biostasis Platform for Cell Therapy Storage and Delivery

A 510k FDA Approval Pathway:

Prostate Cancer Hydrogel Spacer

Our Prostate Cancer Hydrogel Spacer represents strategic platform validation through the FDA 510(k) pathway. This injectable device reduces radiation exposure during prostate cancer treatment, requiring only animal studies rather than human clinical trials for expedited regulatory approval.

Platform Strategy: This 510(k)-cleared product validates our tunable human collagen technology while establishing GMP manufacturing capabilities and FDA regulatory credibility. Success with this streamlined approval pathway creates regulatory momentum for more complex applications including neural interfaces and advanced biomedical devices.

The spacer leverages our platform's biocompatibility advantages, providing a non-inflammatory, natural-tissue-like medium that demonstrates our human ECM technology's safety and efficacy to regulatory authorities.

At Trylle Biologics, we are not just creating products; we are shaping the future of biomedical innovation. Our commitment to breakthrough science, rigorous validation, and translational impact drives everything we do. Whether you are a biomedical researcher, government program manager, investor, or development partner, we invite you to join us in advancing applications that solve problems synthetic materials cannot address.

For more information about our products, services, or investment opportunities, please reach out to us at info@trylleinc.com.